Rep. Price sits on the House Ways and Means Subcommittee on Health that is responsible for crafting healthcare-facing legislation. While holding that role, he invested in:
- Indianapolis’ Eli Lilly
- New York’s Bristol-Meyers Squibb
- Deerfield, Ill.-based Amgen
- San Francisco’s McKesson
- Cambridge, Mass.-based Biogen
- New York’s Pfizer.
Last March, CMS proposed a rule that would change the incentives for prescribing physicians in an attempt to lower Medicare reimbursements from 6 percent of the price of a drug to 2 percent in addition to a small flat fee. Rep. Price opposed the change and co-sponsored legislation that would block the change if it were ever enforced, according to the report.
Rep. Price says a fund manager made the investments and stated plans to divest the stocks after confirmation.
https://www.beckersasc.com/asc-turnarounds-ideas-to-improve-performance/the-43-companies-rep-tom-price-plans-to-divest-after-confirmation-as-hhs-secretary-and-3-he-would-keep.html
More articles on improving health:
The Orthopedic Surgery Center of Arizona’s Dr. David Bailie becomes Integrated Endoscopy CMO, chairman: 5 key notes
5 tips for ASCs to increase revenue and streamline operations
7 things for ASC leaders to know — Jan. 17, 2017
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
